C-Peptide Measurement in Type 1 Diabetes
C-peptide should be measured in insulin-treated patients with type 1 diabetes to assess residual β-cell function and guide classification and management decisions, but C-peptide supplementation is not recommended as it has no established therapeutic role.
When to Measure C-Peptide
According to the most recent 2025 ADA Standards of Care, C-peptide testing is only indicated in people receiving insulin treatment 1. The measurement serves primarily to:
- Distinguish between diabetes types when classification is uncertain (particularly important given that 40% of adults with new type 1 diabetes are initially misdiagnosed)
- Confirm severe insulin deficiency before considering insulin discontinuation
- Guide treatment decisions based on residual β-cell function
Practical Testing Guidelines
The 2025 ADA guidelines provide specific, actionable testing parameters 1:
Timing and Sample Collection:
- A random sample with concurrent glucose within 5 hours of eating can replace formal stimulation testing
- Do not test within 2 weeks of a hyperglycemic emergency
- C-peptide must be measured prior to insulin discontinuation to exclude severe insulin deficiency
Interpretation Algorithm:
- >600 pmol/L (>1.8 ng/mL): Suggests substantial residual function; circumstances of testing don't matter; consider type 2 diabetes or monogenic diabetes
- 200-600 pmol/L (0.6-1.8 ng/mL): Usually consistent with type 1 diabetes or MODY, but may occur in insulin-treated type 2 diabetes (especially with normal/low BMI or long duration)
- <80 pmol/L (<0.24 ng/mL): Confirms severe insulin deficiency; no need to repeat; consistent with type 1 diabetes requiring intensive insulin management
- <600 pmol/L with concurrent glucose <4 mmol/L (<70 mg/dL) or possible fasting: Consider repeating the test
Clinical Utility of Residual C-Peptide
The evidence strongly supports that even minimal residual C-peptide secretion provides meaningful clinical benefits 2:
Glycemic Benefits (C-peptide ≥200 vs. <5 pmol/L):
- 27% lower insulin dose requirements
- HbA1c 4.9 mmol/mol (0.45%) lower during follow-up
- 56% reduction in diabetic ketoacidosis hospital admissions (hazard ratio 0.44)
- 49% reduction in incident retinopathy (odds ratio 0.51)
Hypoglycemia Protection: The relationship between C-peptide and hypoglycemia risk is continuous down to the detection limit (3 pmol/L) 2. Even at levels of 30-200 pmol/L (vs. <5 pmol/L):
- 44% reduction in self-reported severe hypoglycemia (odds ratio 0.56)
- 48% reduction in hospital admissions for hypoglycemia (hazard ratio 0.52)
This contradicts older data suggesting benefits only at higher thresholds (≥130 pmol/L), emphasizing that any detectable C-peptide has clinical value 2.
Optimal Timing for C-Peptide Assessment
C-peptide measurement is most clinically useful 3-5 years after diagnosis 3, 4. At this timepoint:
- Persistence of substantial insulin secretion suggests type 2 diabetes or monogenic diabetes rather than type 1
- The degree of β-cell deficiency becomes clearer
- Classification decisions have greater certainty
However, absent C-peptide at any time confirms absolute insulin requirement and appropriateness of type 1 diabetes management strategies 3.
C-Peptide Supplementation: Not Recommended
There is no evidence supporting therapeutic C-peptide supplementation in type 1 diabetes. The provided evidence focuses exclusively on C-peptide as a biomarker of endogenous insulin secretion, not as a therapeutic agent. C-peptide measurement is valuable for:
- Assessing residual β-cell function
- Guiding treatment decisions
- Serving as a surrogate endpoint in clinical trials of disease-modifying therapies 5, 6, 7
But C-peptide itself is not administered as treatment.
Common Pitfalls to Avoid
Testing too early: C-peptide levels may be elevated at diagnosis due to stress hyperglycemia; wait at least 2 weeks after hyperglycemic emergencies 1
Ignoring glucose context: Low C-peptide with concurrent hypoglycemia or fasting state requires repeat testing unless very low (<80 pmol/L) 1
Assuming type 2 diabetes based solely on detectable C-peptide: Values of 200-600 pmol/L can occur in type 1 diabetes, MODY, or insulin-treated type 2 diabetes 1
Testing non-insulin-treated patients: C-peptide testing is specifically indicated only for those on insulin therapy 1
Role in Disease-Modifying Therapy Trials
C-peptide serves as the most suitable primary outcome for clinical trials aimed at preserving β-cell function 5, 6, 7. It provides:
- Sensitive, validated assessment of β-cell function
- Direct correlation with clinical benefits (glycemic control, reduced complications, lower hypoglycemia risk)
- Feasible measurement under standardized conditions
Recent evidence supports C-peptide as a validated surrogate endpoint that predicts clinical benefits, facilitating development of disease-modifying therapies 6, 7.